Literature DB >> 15068841

Genetic immunization against anthrax.

Darrell Galloway1, Adriane Liner, Joseph Legutki, Alfred Mateczun, Roy Barnewall, James Estep.   

Abstract

The objective of this study was to determine whether a DNA prime-protein boost immunization against the Bacillus anthracis protective antigen (PA) and lethal factor (LF) antigens could induce a protective immune response against significant aerosol challenge in the rabbit model. Rabbits were vaccinated with different regimens of DNA vaccines (Table 1) and aerosol challenged with B. anthracis spores, Ames strain, with an average dose of 50 LD(50s) with a range from 18 to 169 LD(50s.) Of the five vaccinated rabbits that survived, two were immunized intramuscularly (i.m.) with DNA followed with a protein boost and three were immunized subcutaneous (s.q.) with recombinant protein. A major factor predicting survival was the ability of the animal to mount a lasting antibody response to PA. Rabbit sera were collected prior to and following aerosol challenge and titrated for PA antibodies by indirect ELISA. The results of this study indicate that DNA-based immunization against PA and LF induces significant protective immunity against aerosol challenge in the rabbit model and compares favorably with protein-based immunization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15068841     DOI: 10.1016/j.vaccine.2003.09.043

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  21 in total

1.  A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores.

Authors:  G Hermanson; V Whitlow; S Parker; K Tonsky; D Rusalov; M Ferrari; P Lalor; M Komai; R Mere; M Bell; K Brenneman; A Mateczun; T Evans; D Kaslow; D Galloway; P Hobart
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-01       Impact factor: 11.205

2.  Epitope-focused peptide immunogens in human use adjuvants protect rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Daniel Feldman; Fen Yu; Kemp B Cease
Journal:  Vaccine       Date:  2014-11-30       Impact factor: 3.641

3.  Anthrax LFn-PA Hybrid Antigens: Biochemistry, Immunogenicity, and Protection Against Lethal Ames Spore Challenge in Rabbits.

Authors:  Qin Li; Kristina K Peachman; Laurie Sower; Stephen H Leppla; Sathish B Shivachandra; Gary R Matyas; Johnny W Peterson; Carl R Alving; Mangala Rao; Venigalla B Rao
Journal:  Open Vaccine J       Date:  2009

4.  Protection against anthrax by needle-free mucosal immunization with human anthrax vaccine.

Authors:  Mingtao Zeng; Qingfu Xu; Michael E Pichichero
Journal:  Vaccine       Date:  2007-01-26       Impact factor: 3.641

5.  An anthrax subunit vaccine candidate based on protective regions of Bacillus anthracis protective antigen and lethal factor.

Authors:  Les W Baillie; Theresa B Huwar; Stephen Moore; Gabriela Mellado-Sanchez; Liliana Rodriguez; Brendan N Neeson; Helen C Flick-Smith; Dominic C Jenner; Helen S Atkins; Rebecca J Ingram; Danny M Altmann; James P Nataro; Marcela F Pasetti
Journal:  Vaccine       Date:  2010-08-04       Impact factor: 3.641

6.  Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.

Authors:  Jon Oscherwitz; Fen Yu; Jana L Jacobs; Kemp B Cease
Journal:  Clin Vaccine Immunol       Date:  2013-01-02

7.  Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding.

Authors:  Zhaochun Chen; Mahtab Moayeri; Huaying Zhao; Devorah Crown; Stephen H Leppla; Robert H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-27       Impact factor: 11.205

8.  Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen.

Authors:  Jon Oscherwitz; Fen Yu; Jana L Jacobs; Te-Hui Liu; Philip R Johnson; Kemp B Cease
Journal:  Infect Immun       Date:  2009-06-01       Impact factor: 3.441

9.  A DNA vaccine targeting the receptor-binding domain of Clostridium difficile toxin A.

Authors:  David F Gardiner; Talia Rosenberg; Jerry Zaharatos; David Franco; David D Ho
Journal:  Vaccine       Date:  2009-04-09       Impact factor: 3.641

Review 10.  Anthrax vaccination strategies.

Authors:  Robert J Cybulski; Patrick Sanz; Alison D O'Brien
Journal:  Mol Aspects Med       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.